Matsalolin da suka shafi lafiyar Parkinson na iya rinjayar tsira
Kwayoyin Parkinson na kwayar cutar ne kawai (cututtukan cututtuka na kwayar cutar), kuma kodayake ba mutuwa bane, bincike yana nuna cewa zai iya rinjayar rayuwar rai.
Wani binciken a cikin Tarihin Magungunan Labaran ya bincika tsawon shekara shida na kimanin kusan 140,000 Medicare da ke fama da cutar Parkinson a Amurka. A lokacin shekaru shida, kashi 64 cikin 100 na mahalarta da cutar Parkinson sun wuce.
Rashin mutuwa na wadanda ke tare da Parkinson ya kasance a yanzu idan aka kwatanta da masu lafiya Medicare waɗanda basu da kwayar cutar Parkinson ko wasu cututtuka na kowa, ciki har da:
- cututtukan zuciya ko ciwo na zuciya
- cuta mai ruɗar cuta na kullum
- colon, huhu, ko ciwon nono
- ciwon sukari
- bugun jini
- na kullum cutar koda
- raunin ƙyallen
- Alzheimer ta dementia
Lokacin da ake sarrafawa ga masu rikitarwa kamar shekarun, tsere, da jinsi, an samu kimanin shekaru shida na mutuwa tsakanin mutane tare da Parkinson na kusan kusan sau hudu fiye da wadanda Medicare ke amfana ba tare da cutar ko wasu cututtuka na kowa ba.
Bugu da kari, mutuwar wadanda ke fama da cutar Parkinson sun kasance kamar wadanda ke da lalatawar hanzari, lalatacciyar Alzheimer, ko ciwon zuciya na kwanan nan-ko da yake ya fi yadda waɗanda aka saba samu da ciwon daji, bugun jini, ischemic cututtukan zuciya, ko cutar ta hanyar ciwon huhu.
Menene ma'anar wannan? Yana nuna cewa samun ciwon kwayar cutar Parkinson yana tasiri ga tsawon rai.
Amma tuna, ba kwayar cutar Parkinson kanta ba ce. Maimakon haka, matsalolin kamar kamuwa da cuta ko lalacewar da ke faruwa ne sakamakon sakamakon ciwon kwayar cutar Parkinson wanda ya haifar da gajeren rai.
Matsayin Dementia da Age
Dementia kuma tana taka muhimmiyar rawa wajen rayuwa tare da Parkinson.
A ƙarshen binciken da ke sama, kimanin kashi 70 cikin dari na yawan mutanen da aka gano da kwayar cutar Parkinson sun samu lafiya, kuma wadanda ke da lalata suna da sauƙin rayuwa kamar yadda aka kwatanta da waɗanda ba tare da su ba.
Wannan yana nufin cewa wadanda ke da lalatawa sun fi mutuwa a cikin shekaru shida da waɗanda ba tare da lalata ba. Bugu da ƙari, binciken kimiyya ya nuna cewa karuwa yana da alaka da haɗarin mutuwa.
Yana da mahimmanci mu tuna da yadda cutar ta kwayar cutar mutum ta nuna kuma cigaban ci gaba mai sauƙi, kuma mai binciken likitancin mutum ba zai iya hango hangen nesa ba.
A wasu kalmomi, akwai wasu alamu ko alamomin da ke ba da damar likita su yi la'akari da tsawon lokaci. Wani tsofaffi da kuma ciwon lalata suna da alaka da haɗarin mutuwa.
Shekaru na Ƙarshe na Rayuwa a Cututtukan Parkinson
Har ila yau binciken ya bincikar kusan asibitoci 45,000 a cikin mutanen da ke fama da kwayar cutar Parkinson, wanda ke nufin ma'anar ƙarshen rayuwarsu. Daga wadanda ke tare da PD, dalilai da suka fi dacewa don zama a asibiti sune:
- Kamuwa da cuta (kusan kashi 21 cikin dari na asibiti)
- Ciwon zuciya (kashi 18.5)
- Lung cutar da ba daga kamuwa da cuta (kusan kashi 13)
Kadan ƙananan haddasawa ga asibiti suna da matsalolin da ke cikin ciki ko intestines, tsokoki, tsarin mai juyayi, ko tsarin endocrin (alal misali, ciwon sukari).
Ba abin mamaki bane cewa kamuwa da cuta shine asibiti mafi yawan gaske kafin mutuwar, kamar yadda mutane da Parkinson ke da wuya su bunkasa yawan cututtuka saboda cutar. Alal misali, rashin lafiyar magunguna a Parkinson ya kara yawan haɗarin mutum na bunkasa cututtukan urinary, wanda zai zama barazanar rai idan ba a gano shi ba kuma ya bi da shi sosai.
Bugu da ƙari, bincike ya nuna cewa ciwon ciwon huhu yana da sau 3,8 sau da yawa a cikin mutane tare da Parkinson ta idan aka kwatanta da yawan jama'a.
Har ila yau, an bayar da rahoton cewa shine babban dalilin mutuwar mutane da Parkinson.
Zuciyar ciwon huhu yana haifar da matsaloli masu haɗari, wanda ke haifar da abun ciki cikin ciki. Rashin haɓaka da kuma rigidity, wanda zai iya shafe phlegm cire, kuma yana taimakawa wajen bunkasa ciwon huhu a cikin mutane tare da Parkinson.
Tabbas, cututtukan zuciya shine babbar hanyar mutuwa a Amurka, saboda haka ba abin mamaki bane cewa mutanen da ke da kwayar cutar Parkinson suna asibiti saboda wannan kafin mutuwar. Abin sha'awa, masu marubuta na binciken sun ɗauka cewa wasu likitoci da ke kula da mutane tare da Parkinson na iya nuna alamar cututtuka na zuciya ko cutar huhu (alal misali, gajiya, rauni, da matsala) kamar alamun da Parkinson ya yi.
Kalma Daga
Baya ga kula da lafiyar lafiyar Parkinson, yana da mahimmanci don kula da lafiyar lafiyarka. Wannan na nufin ziyartar likitan likitanku na lokaci-lokaci don kulawa da rigakafi kamar annobar muradin shekara da nunawa kan ciwon daji - alal misali, mammogram don nunawa kan ciwon nono da kuma maganin maganin cutar kanjamau.
Malamin kulawa na farko zai iya kimantawa game da halayen haɗari da suka shafi halayen zuciya da shanyewar jiki, da kuma bayar da shawarwari a kan motsa jiki, shan taba, amfani da giya, damuwa, ko kuma sauran matsalolin kiwon lafiya. Ziyarci na yau da kullum zuwa likita ko likitancinku na farko zai ba shi damar daukar nau'in cututtuka na kwayan cuta kamar cututtuka na urinary kafin su yi tsanani.
A wasu kalmomi, yayin da ciwon cututtukan Parkinson zai iya tasiri ga rayuwarku ko rayuwar ku ƙaunatacciyar rai, bisharar ita ce rayuwa mai kyau (kuma mai yiwuwa tsawon lokaci) za a iya inganta tare da kulawa mai kyau. Tabbatar tabbatar da biyan kuɗi tare da likitanku, kuma ku shiga cikin maganin kwantar da hankali kamar aikin jiki da aikin, musamman a farkon cutar.
> Sources:
> Macleod AD, Taylor KS, Kamfanin CE. Rashin mutuwar cutar cutar Parkinson: nazari mai mahimmanci da meta-bincike. Yanayin Masa . 2014 Nov; 29 (13): 1615-22.
> Martinez-Ramirez D. et al. Adadin zuwan ƙwayar cuta a cikin asibiti Kwayoyin cututtuka na kwayar cutar Parkinson: nazarin giciye. BMC Neurol . 2015; 15: 104.
> Foundation Foundation Parkinson. Menene Parkinson?
> Pinter B, et al. Rashin mutuwar cutar cutar Parkinson: binciken shekaru 38. Yanayin Masa . 2015 Feb, 30 (2): 266-9.
> Willis AW, Schootman M, Kung N, Evanoff BA, Perlmutter JS, Racette BA. Ma'aikata na rayuwa a Parkinsons > cuta. Arch Neurol. 2012 May, 69 (5): 601-07.